Get Artiva Biotherapeutics alerts:Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artiva Biotherapeutics 1 0 4 1 2.83 Artiva Biotherapeutics Competitors 7266 12653 38649 1233 2.57Artiva Biotherapeutics presently has a consensus price target of $19.00, indicating a potential upside of 325.06%. Given Artiva Biotherapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Artiva Biotherapeutics is more favorable than its rivals. ProfitabilityNet Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -49.99% -44.05% Artiva Biotherapeutics Competitors -824.61% -116.10% -28.91%Valuation and EarningsThis table compares Artiva Biotherapeutics and its rivals’ net margins, return on equity and return on assets. Gross Revenue Net Income Price/Earnings Ratio Artiva Biotherapeutics $250,000.00 -$65.37 million -1.73 Artiva Biotherapeutics Competitors $942.56 million -$41.92 million 8.73Artiva Biotherapeutics’ rivals have higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics Company Profile(Get Free Report)Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.